138 related articles for article (PubMed ID: 9210357)
1. Prognostic factors in malignant melanoma.
Kashani-Sabet M; Leong SP; Sagebiel R
Surg Oncol Clin N Am; 1997 Jul; 6(3):599-623. PubMed ID: 9210357
[TBL] [Abstract][Full Text] [Related]
2. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors in thin cutaneous malignant melanoma].
Massi D; Franchi A; Santucci M
Pathologica; 2002 Dec; 94(6):282-9. PubMed ID: 12540991
[TBL] [Abstract][Full Text] [Related]
4. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.
Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
Melanoma Res; 2007 Dec; 17(6):393-9. PubMed ID: 17992123
[TBL] [Abstract][Full Text] [Related]
5. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma.
Wobser M; Siedel C; Schrama D; Bröcker EB; Becker JC; Vetter-Kauczok CS
Arch Dermatol Res; 2006 Feb; 297(8):352-7. PubMed ID: 16395613
[TBL] [Abstract][Full Text] [Related]
6. Melanoma patient staging: histopathological versus molecular evaluation of the sentinel node.
Davids V; Kidson SH; Hanekom GS
Melanoma Res; 2003 Jun; 13(3):313-24. PubMed ID: 12777989
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in patients with thick cutaneous melanoma (> 4 mm).
Zettersten E; Sagebiel RW; Miller JR; Tallapureddy S; Leong SP; Kashani-Sabet M
Cancer; 2002 Feb; 94(4):1049-56. PubMed ID: 11920475
[TBL] [Abstract][Full Text] [Related]
8. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
9. Tumor lymphangiogenesis and melanoma metastasis.
Rinderknecht M; Detmar M
J Cell Physiol; 2008 Aug; 216(2):347-54. PubMed ID: 18481261
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
[TBL] [Abstract][Full Text] [Related]
11. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
12. A model for pretest probability of lymph node metastasis from cutaneous Melanoma.
Vollmer RT; Seigler HF
Am J Clin Pathol; 2000 Dec; 114(6):875-9. PubMed ID: 11338476
[TBL] [Abstract][Full Text] [Related]
13. Insights into the mechanisms of lymph node metastasis.
Nathanson SD
Cancer; 2003 Jul; 98(2):413-23. PubMed ID: 12872364
[TBL] [Abstract][Full Text] [Related]
14. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
[TBL] [Abstract][Full Text] [Related]
15. Pathology of melanocytic lesions: new, controversial, and clinically important issues.
Scolyer RA; Thompson JF; Stretch JR; Sharma R; McCarthy SW
J Surg Oncol; 2004 Jul; 86(4):200-11. PubMed ID: 15221927
[TBL] [Abstract][Full Text] [Related]
16. [Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma].
Eigentler TK; Radny P; Kamin A; Weide B; Caroli UM; Garbe C
J Dtsch Dermatol Ges; 2005 Aug; 3(8):592-8. PubMed ID: 16033477
[TBL] [Abstract][Full Text] [Related]
17. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
18. Molecular staging for patients with malignant melanoma.
Shivers S; Jakub J; Pendas S; Reintgen D
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1665-74. PubMed ID: 18020932
[TBL] [Abstract][Full Text] [Related]
19. The natural course of cutaneous melanoma.
Leiter U; Meier F; Schittek B; Garbe C
J Surg Oncol; 2004 Jul; 86(4):172-8. PubMed ID: 15221923
[TBL] [Abstract][Full Text] [Related]
20. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
